Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Giri, 2017, Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation, JCO Precis Oncol, 1, 1 Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022 Pennington, 2014, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas, Clin Cancer Res, 20, 764, 10.1158/1078-0432.CCR-13-2287 Scott, 2015, Poly (ADP-ribose) polymerase inhibitors: recent advances and future development, J Clin Oncol, 33, 1397, 10.1200/JCO.2014.58.8848 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Boudadi, 2018, Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer, Oncotarget, 9, 28561, 10.18632/oncotarget.25564 De Bono, 2018, KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 36, 5007, 10.1200/JCO.2018.36.15_suppl.5007 Carter, 2019, Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer, Eur Urol, 75, 743, 10.1016/j.eururo.2018.09.021 Giri, 2019, Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing, Prostate, 79, 333, 10.1002/pros.23739 Nicolosi, 2019, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines, JAMA Oncol, 5, 523, 10.1001/jamaoncol.2018.6760 Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 Carlo, 2018, Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium, JCO Precis Oncol, 2018 Zon, 2009, American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment, J Clin Oncol, 27, 986, 10.1200/JCO.2008.16.3691 Mohler Parent, 2018, Update on (18)F-fluciclovine PET for prostate cancer imaging, J Nucl Med, 59, 733, 10.2967/jnumed.117.204032 Cantiello, 2018, Comparison between 64Cu-PSMA-617 PET/CT and 18F-choline PET/CT imaging in early diagnosis of prostate cancer biochemical recurrence, Clin Genitourin Cancer, 16, 385, 10.1016/j.clgc.2018.05.014 Miyahira, 2018, Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group, Prostate, 78, 775, 10.1002/pros.23642 Giri, 2018, Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017, J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173 National Comprehensive Cancer Network Riley, 2012, Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors, J Genet Couns, 21, 151, 10.1007/s10897-011-9462-x Robson, 2015, American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility, J Clin Oncol, 33, 3660, 10.1200/JCO.2015.63.0996 Sanda, 2018, Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options, J Urol, 199, 683 Hoskovec, 2018, Projecting the supply and demand for certified genetic counselors: a Workforce study, J Genet Couns, 27, 16, 10.1007/s10897-017-0158-8 Stoll, 2018, The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine, Am J Med Genet C Semin Med Genet, 178, 24, 10.1002/ajmg.c.31602 World Health Organization